Urology Medical News about hypoxia inducible factor

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. 2008 Exclusive Survey—Earnings: Good news for primary care income

3. Medicare pay-for-reporting effort draws fire from frustrated doctors

4. Debunking Myths in the US Healthcare System

5. Doctors and the DEA Free full text

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Clinical implications of hypoxia inducible factor in renal cell carcinoma
Urologic Oncology: Seminars and Original Investigations, 06/29/09

Smaldone MC et al. - In a review of the clinical implications of hypoxia inducible factor (HIF) in renal cell carcinoma (RCC), this report provides a directed review of recent discoveries defining the role of HIF in renal tumorigenesis and their relevance to clinical advances in targeted therapy for advanced RCC.

Methods

Management of RCC has made considerable strides in the past decade, due in large part to identification of the von Hippel Lindau (VHL) tumor suppressor as a negative regulator of HIF-α protein expression.

Results

Stabilization of HIF-α appears to be critical for renal tumorigenesis, and is observed even in VHL-independent RCC.
An understanding of the pathways that regulate expression and activation of the different HIF-α isoforms is key to delineating the mechanism of renal transformation and for development of novel therapeutics.
A number of agents targeting HIF-α or its transcriptionally-regulated genes have shown promise in treatment of RCC.
More effective treatment strategies are still needed.

<< Previous
Relationship Between Platelet Activation and Acute Rejection...

Next >>
Livin may serve as a marker for prognosis of bladder cancer...